Published in Health Insurance Week, September 9th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Cytopia.
Report 1: Cytopia Limited (ASX:CYT) announced today the formation of an oncology clinical advisory panel to guide future development of CYT997, the company's lead small-molecule vascular-disrupting agent (VDA), into Phase II development. The Panel will also assist the company with planning for its other anticancer programmes.
The advisory panel is comprised of eminent medical oncologists from the United States with extensive drug development and regulatory experience. Two leading...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Insurance Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.